Generation of recombinant antibody fragments that target canine dendritic cells by phage display technology

Veterinary and Comparative Oncology

Volumn 9, Issue 3, 2011, Pages 183-195

  Fitting, J ^a   Killian, D ^b   Junghanss, C ^b   Willenbrock, S ^c   Murua Escobar, H ^c   Lange, S ^b   Nolte, I ^c   Barth, S ^a,d   Tur, M K ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^d FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

Cancer; Dendritic cells; Dogs; Phage display technology; ScFv antibody

Indexed keywords

CD34 ANTIGEN; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL; ANTIBODY AFFINITY; ARTICLE; DENDRITIC CELL; DOG; FEMALE; IMMUNOLOGY; MALE; MOLECULAR GENETICS; MONONUCLEAR CELL; PEPTIDE LIBRARY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY AFFINITY; ANTIGENS, CD34; DENDRITIC CELLS; DOGS; FEMALE; LEUKOCYTES, MONONUCLEAR; MALE; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES;

ANIMALIA; CANIS FAMILIARIS;

EID: 80051809358     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2010.00246.x     Document Type: Article

References (31)

1. Garcia MJA, Ward EM, Center MM, Hao Y, Siegel RI and Thun MJ. Global Cancer Facts and Figures. Available at:.
2. Paoloni MC and Khanna C. Comparative oncology today. The Veterinary Clinics of North America. Small Animal Practice 2007; 37: 1023-1032; v.
3. Andrade FH, Figueiroa FC, Bersano PR, Bissacot DZ and Rocha NS. Malignant mammary tumor in female dogs: environmental contaminants. Diagnostic Pathology 2010; 5: 45.
4. Bukowski JA, Wartenberg D and Goldschmidt M. Environmental causes for sinonasal cancers in pet dogs, and their usefulness as sentinels of indoor cancer risk. Journal of Toxicology and Environental Health Part A 1998; 54: 579-591.
5. Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L, Breen M, Kitchell B, McNeil E, Modiano JF, Niemi S, Comstock KE, Ostrander E, Westmoreland S and Withrow S. The dog as a cancer model. Nature Biotechnology 2006; 24: 1065-1066.
6. Bergman PJ. Anticancer vaccines. The Veterinary Clinics of North America. Small Animal Practice 2007; 37: 1111-1119; vi-vii.
7. Steinman RM, Hawiger D and Nussenzweig MC. Tolerogenic dendritic cells. Annual Review of Immunology 2003; 21: 685-711.
8. Banchereau J and Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nature Reviews. Immunology 2005; 5: 296-306.
9. Aarntzen EH, Figdor CG, Adema GJ, Punt CJ and de Vries IJ. Dendritic cell vaccination and immune monitoring. Cancer Immunology, Immunotherapy 2008; 57: 1559-1568.
10. Hagglund HG, McSweeney PA, Mathioudakis G, Bruno B, Georges GE, Gass MJ, Moore P, Sale GE, Storb R and Nash RA. Ex vivo expansion of canine dendritic cells from CD34+ bone marrow progenitor cells. Transplantation 2000; 70: 1437-1442.
11. Altmann S, Lange S, Pommerencke J, Murua Escobar H, Bullerdiek J, Nolte I, Freund M and Junghanss C. High Mobility Group Box 1-Protein expression in canine haematopoietic cells and influence on canine peripheral blood mononuclear cell proliferative activity. Veterinary Immunology and Immunopathology 2008; 126: 367-372.
12. Tur MK, Rothe A, Huhn M, Goerres U, Klimka A Stocker M, Engert A, Fischer R, Finner R and Barth S. A novel approach for immunization, screening and characterization of selected scFv libraries using membrane fractions of tumor cells. International Journal of Molecular Medicine 2003; 11: 523-527.
13. Tur MK, Sasse S, Stocker M, Djabelkhir K, Huhn M, Matthey B, Gottstein C, Pfitzner T, Engert A and Barth S. An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines. International Journal of Molecular Medicine 2001; 8: 579-584.
14. MRC. (accessed June 2010).
15. Rouas-Freiss N, Moreau P, Ferrone S and Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Research 2005; 65: 10139-10144.
16. Hamai A, Benlalam H, Meslin F, Hasmim M, Carre T, Akalay I, Janji B, Berchem G, Noman MZ and Chouaib S. Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens 2010; 75: 1-8.
17. Ilett EJ, Prestwich RJ and Melcher AA. The evolving role of dendritic cells in cancer therapy. Expert Opinion on Biological Therapy 2010; 10: 369-379.
18. Martin-Fontecha A, Lanzavecchia A and Sallusto F. Dendritic cell migration to peripheral lymph nodes. Handbook of Experimental Pharmacology 2009; 188: 31-49.
19. Verdijk P, Aarntzen EH, Punt CJ, de Vries IJ and Figdor CG. Maximizing dendritic cell migration in cancer immunotherapy. Expert Opinion on Biological Therapy 2008; 8: 865-874.
20. Tur MK, Huhn M, Sasse S, Engert A and Barth S. Selection of scFv phages on intact cells under low pH conditions leads to a significant loss of insert-free phages. Biotechniques 2001; 30: 404-408.
21. Akins EJ and Dubey P. Noninvasive imaging of cell-mediated therapy for treatment of cancer. Journal of Nuclear Medicine 2008; 49(Suppl. 2): 180S-195S.
22. De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, Strijk SP, Ruers TJ, Boerman OC, Oyen WJG, Adema GA, Punt CJ and Figdor CG. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Research 2003; 63: 12-17.
23. Kiessling F. Noninvasive cell tracking. Handbook of Experimental Pharmacology 2008; 185/2: 305-321.
24. Bratkovic T. Progress in phage display: evolution of the technique and its applications. Cellular and Molecular Life Sciences 2009; 67: 749-767.
25. Nielsen U and Marks J. Affinity maturation of phage antibodies. In: Phage Display A Practical Approach, edn, Clackson T and Lowman H, eds., Oxford, Oxford University Press, 2004; 266: 309-311.
26. Eisenhardt SU, Schwarz M, Bassler N and Peter K. Subtractive single-chain antibody (scFv) phage-display: tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules. Nature Protocols 2007; 2: 3063-3073.
27. Braunagel M. Construction of semisynthetic antibody libraries. Methods in Molecular Biology 2003; 207: 123-132.
28. Cwirla SE, Peters EA, Barrett RW and Dower WJ. Peptides on phage: a vast library of peptides for identifying ligands. Proceedings of the National Academy of Sciences of the United States of America 1990; 87: 6378-6382.
29. Marcus WD, Wang H, Lohr D, Sierks MR and Lindsay SM. Isolation of an scFv targeting BRG1 using phage display with characterization by AFM. Biochemical and Biophysical Research Communications 2006; 342: 1123-1129.
30. Beekwilder J, Rakonjac J, Jongsma M and Bosch D. A phagemid vector using the E. coli phage shock promoter facilitates phage display of toxic proteins. Gene 1999; 228: 23-31.
31. Hust M, Meysing M, Schirrmann T, Selke M, Meens J Gerlach GF, and Dubel S. Enrichment of open reading frames presented on bacteriophage M13 using hyperphage. Biotechniques 2006; 41: 335-342.